Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel therapy for COPD.

M J Leckie1, S A Bryan, T T Hansel

  • 1National Heart and Lung Institute, Royal Brompton Clinical Studies Unit, Imperial College, London, UK.

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of granulocyte pharmacodynamics in whole blood by flow cytometry.

Methods in molecular medicine·2011
Same author

Automated quantitation of peripheral blood neutrophil activation in patients with myocardial ischaemia.

International journal of cardiology·2004
Same author

Sputum T lymphocytes in asthma, COPD and healthy subjects have the phenotype of activated intraepithelial T cells (CD69+ CD103+).

Thorax·2003
Same author

Biological treatments for systemic lupus erythematosus.

Scandinavian journal of rheumatology·2002
Same author

Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis.

Rheumatology (Oxford, England)·2002
Same author

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

Lancet (London, England)·2001
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Chronic obstructive pulmonary disease (COPD) is rising globally, with limited understanding of its cause and poor response to current treatments. New therapies are in development to slow lung function decline in COPD patients.

Area of Science:

  • Pulmonology
  • Respiratory Medicine

Background:

  • The global incidence of Chronic Obstructive Pulmonary Disease (COPD) is increasing.
  • Pathogenesis of COPD is less understood compared to asthma, with limited response to existing therapies.
  • Cigarette smoking is the primary cause of COPD, making smoking cessation a critical management step.

Purpose of the Study:

  • To review the current state of COPD treatment and development.
  • To highlight the need for novel therapeutic targets and improved management strategies for COPD.
  • To emphasize the importance of reliable Phase II decision-making for developing new COPD therapies.

Main Methods:

  • Review of current and developing therapies for COPD.
  • Discussion of challenges in COPD research and treatment.

Related Experiment Videos

  • Comparison of COPD patient care with asthma patient care.

    • Main Results:

    • Several new therapies are under development, including novel bronchodilators (e.g., tiotropium bromide).
    • Research is focused on blocking inflammation and combating proteases and oxidants.
    • The long-term goal is to develop therapies that slow the accelerated loss of lung function in COPD.

    Conclusions:

    • There is an urgent need to identify novel therapeutic targets for COPD.
    • Improved therapies are required to effectively manage COPD and slow disease progression.
    • Further research and development are crucial for better COPD patient outcomes.